Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMK96CE)

Drug Name
GC-1113 Drug Info
Indication
Disease Entry ICD 11 Status REF
Anemia 3A00-3A9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMK96CE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erythropoietin (EPO) TTQG4NR EPO_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Erythropoietin (EPO) DTT EPO 4.717 3.225 1 3.781
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Anemia
ICD Disease Classification 3A00-3A9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Erythropoietin (EPO) DTT EPO 5.72E-01 -0.15 -0.83
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01363934) To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin. U.S. National Institutes of Health.
2 A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia. Arch Pharm Res. 2012 May;35(5):757-9.